Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of cetuximab treatment in squamous cell carcinomas.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Apr 2010

Nestor Marika

Abstract excerpt

The purpose of this study was to assess the effects of the monoclonal antibody cetuximab in a panel of cultured squamous cell carcinoma cell lines. This antibody, targeting the epidermal growth factor receptor (EGFR), is emerging as a promising agent for treatment of several cancers. As this antibody comes into clinical use, the identification of predictive markers of therapeutic benefit remains a pressing issue....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Squamous Cell

Share to Cell Cycle

Share to Cetuximab

Share to ErbB Receptors

Share to Head and Neck Neoplasms

Source

Identifiers

PMID: 20358427
DOI: 10.1007/s13277-010-0018-8

Genes

EGFR
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of cetuximab treatment in squamous cell carcinomas.PMID 20358427Read ↗

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.Semantic proximity Read ↗

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.Semantic proximity Read ↗

Cetuximab, its clinical use and future perspectives.Semantic proximity Read ↗

Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.Semantic proximity Read ↗

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).Semantic proximity Read ↗

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell linesSemantic proximity Read ↗

Combination effect of cetuximab with radiation in colorectal cancer cells.Semantic proximity Read ↗

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.Semantic proximity Read ↗

Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status.Semantic proximity Read ↗

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.Semantic proximity Read ↗

Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy <i>In vivo</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.